摘要
目的:比较喹硫平与氯丙嗪治疗慢性精神分裂症的疗效和安全性。方法:将68例慢性精神分裂症患者随机分两组,分别以喹硫平和氯丙嗪治疗,疗程8周。采用阳性与阴性症状量表(PANSS)及副反应量表(TESS)评定疗效及不良反应。结果:治疗8周后,两组PANSS总评分均较治疗前显著下降。但是,喹硫平组阴性症状评分的下降要高于氯丙嗪组,两者有显著性差异(P<0.05),且喹硫平组的不良反应要低于氯丙嗪组(P<0.05)。结论:喹硫平与氯丙嗪治疗慢性精神分裂症患者对阴性症状优于氯丙嗪,不良反应轻、安全性好。
Objective:to compare the efficacy and safety of quetiapine and chlorpromszine in the treatment of chronic schizophrenia. Methods:68 patients with chronic schizophrenia( according to ICD -10) were divided into two groups who treated with quetiapine or chlorpromszine respectively for 8 weeks. The positive and negative syndrome scale (PNASS) and treatment emergent side effect scale (TESS) were used to evaluate efficacy and adverse effect before an after treatment repectively. Results: There was significant differences between before and after the treatment of two groups in overall response showed by the reduction of the scores of total scale of PANSS at $ weeks treatment. But, the scores of negative syndrome of PANSS in queteapine group was significantly lower than in chlorpromszine group at 8 week after treatment ( P 〈 0.05 ) , so do the sores of TESS. Conclusions : The efficacy on negative syn drome of quetiapine is better than that of chlorpromszine , and quetiapine have fewer side effects than chlorpromszine in the treatment of chronic schizophrenia.
出处
《中国民康医学》
2013年第5期69-70,共2页
Medical Journal of Chinese People’s Health
关键词
喹硫平
氯丙嗪
慢性精神分裂症
Quetiapine
Chlorpromszine
Chronic schizophrenia